Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 /
抑制剂/激动剂
天然产物 囊泡 肿瘤 内分泌与代谢疾病
/
NF-κB
伞科 帕金森与阿尔茨海默症 肿瘤干细胞 Toll样受体 PPAR Signaling Pathway Wnt Signaling Pathway 细胞焦亡 胰腺癌 衰老 宫颈癌
/
NF-κB
IKK 橄榄属
/ Bardoxolone/巴多索隆

Bardoxolone/巴多索隆 {[allProObj[0].p_purity_real_show]}

货号：A165469 同义名： 齐墩果烷三萜化合物 / CDDO; RTA 401

Bardoxolone是一种核因子 Nrf-2 激活剂，抑制 Z-VAD-FMK 诱导的坏死性凋亡，降低 Paclitaxel (PAC) 诱导的神经元细胞线粒体损伤。

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Bardoxolone/巴多索隆 化学结构 CAS号：218600-44-3
Bardoxolone/巴多索隆 化学结构
CAS号：218600-44-3
Bardoxolone/巴多索隆 3D分子结构
CAS号：218600-44-3
Bardoxolone/巴多索隆 化学结构 CAS号：218600-44-3
Bardoxolone/巴多索隆 3D分子结构 CAS号：218600-44-3
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} 		{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} 现货 1周 咨询 - +
购物车0 收藏 询单

Bardoxolone/巴多索隆 纯度/质量文件 产品仅供科研

货号：A165469 标准纯度： {[allProObj[0].p_purity_real_show]}
批次查询： 批次纯度:

全球学术期刊中引用的产品

• Nature, 2025, 645, 793-800. Ambeed. [ A201204 , A444152 , A344107 , A952055 ]
• Cell, 2025. Ambeed. [ A122167 ]
• Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]
• Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed. [ A104916 ]
• Nat. Nanotechnol., 2025. Ambeed. [ A243018 , A1216705 , A522597 , A125401 , A1355641 ]
更多 >
产品名称 NF-κB ↓ 其他靶点 纯度
Ammonium pyrrolidine-1-carbodithioate ✔ 98%
QNZ ++++

NF-κB, IC50: 11 nM

 		99%+
Sodium 4-Aminosalicylate Dihydrate ✔ 98%
Sodium Salicylate ✔ 95%
Parthenolide ✔ p53 97% HPLC
JSH-23 +

NF-κB, IC50: 7.1 μM

 		98%
Phenethyl caffeate ✔ 98%
Andrographolide ✔ 98+%
Curcumin ✔ HDAC,Nrf2 98%
SC75741 +++

NF-κB, EC50: 200 nM

 		99%+
CBL0137 HCl ++

NF-κB, EC50: 0.47 μM

 		p53 99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Bardoxolone/巴多索隆 生物活性

描述 Bardoxolone (CDDO) serves as a novel activator of the nuclear regulatory factor (Nrf-2), particularly beneficial for studying chronic kidney disease. Additionally, Bardoxolone acts as a potent inhibitor of necroptosis induced by Z-VAD-FMK[1].

Bardoxolone/巴多索隆 细胞实验

Cell Line
Concentration Treated Time Description References
Primary microglia 100 nM 24 hours Inhibited LPS-induced TNF and IL-1β mRNA expression J Neuroinflammation. 2008 May 12;5:14.
BV2 microglia cell line 10 nM 17 hours Inhibited LPS-induced TNF mRNA expression J Neuroinflammation. 2008 May 12;5:14.
FET cells 10–300 nM 24 hours CDDO-Me induced the expression of 15-PGDH in a dose-dependent manner and increased 15-PGDH promoter luciferase activity through direct transcriptional regulation. J Clin Invest. 2014 Jun;124(6):2472-82.
EL-4, MC38, and LLC tumor cells >1 μM 24 hours To evaluate the direct antitumor effect of CDDO-Me on tumor cells. CDDO-Me showed significant antitumor activity at concentrations higher than 1 μM. Clin Cancer Res. 2010 Mar 15;16(6):1812-23.
MDSC (Gr-1+CD11b+ cells) 25-100 nM 24 hours To evaluate the effect of CDDO-Me on the immune suppressive activity of MDSC. CDDO-Me significantly increased NQO1 expression, reduced ROS levels, and completely abrogated MDSC-mediated suppression of CD8+ T cell responses. Clin Cancer Res. 2010 Mar 15;16(6):1812-23.
E18-14C-27 cells 0.3 μmol/L 72 hours Measure cell proliferation, CDDO-Me significantly inhibited cell proliferation Clin Cancer Res. 2008 Jul 15;14(14):4556-63.
MN9D dopaminergic cell line 10 nM 16-20 hours Inhibited ROS accumulation induced by BV2 microglia conditioned media J Neuroinflammation. 2008 May 12;5:14.
Primary peritoneal macrophages 100 nM 24 hours Inhibited LPS-induced TNF and IL-1β mRNA expression J Neuroinflammation. 2008 May 12;5:14.

Bardoxolone/巴多索隆 动物实验

Species
Animal Model
Administration Dosage Frequency Description References
Mice Nrf2+/+ and Nrf2−/− mice Intraperitoneal injection 3 mg/kg Single dose, sacrificed 24 hours later To verify the efficacy of CDDO-Me in inducing Nrf2 signaling in mouse kidneys, immunoblot, qPCR, and immunohistochemical analyses showed upregulation of Nqo1 expression in Nrf2+/+ mice but not in Nrf2?/? mice. Kidney Int. 2015 Dec;88(6):1261-1273
Mice Ang II-induced AAA model Intraperitoneal injection 1.25 mg/kg/day Once daily for 4 weeks To evaluate the effect of BM on AAA progression induced by high ILF3 expression, results showed that BM treatment alleviated the severity of AAA lesions. Nat Commun. 2024 Aug 23;15(1):7249.
Mice Chronic kidney disease model Intraperitoneal injection 10 μmol/kg Daily for 7 days To study the effect of Nrf2 activation on proteinuria, results showed CDDO-Im significantly increased proteinuria Kidney Int. 2021 Jan;99(1):102-116
Mice Smad4Tko mice and wild-type mice Oral 250 ng per mouse per day 3 times per week for 1 month CDDO-Me markedly increased survival, reduced inflammation, and inhibited spontaneous colon tumorigenesis. J Clin Invest. 2014 Jun;124(6):2472-82.
BALB/c mice Alternaria extract-induced airway inflammation model Intraperitoneal injection 50 μg Once daily for 18 days To evaluate the protective effects of CDDO-Me on airway inflammation, results showed CDDO-Me treatment significantly inhibited Alternaria-induced airway eosinophilia, IL-5 and IL-13 expression, and lung pathological changes. Allergy. 2017 Oct;72(10):1521-1531.
C57BL/6 mice EL-4 thymoma, LLC lung carcinoma, and MC38 colon carcinoma models Oral 60-150 mg/kg Daily administration for 7-14 days To evaluate the effect of CDDO-Me on MDSC function and tumor growth. CDDO-Me significantly reduced ROS levels in MDSC, eliminated their immune suppressive activity, and delayed tumor growth. In immune-deficient mice, the antitumor effect of CDDO-Me was not significant, indicating that its effect is largely mediated by the immune system. Clin Cancer Res. 2010 Mar 15;16(6):1812-23.
Mice Spontaneous lupus model Oral gavage 3 mg/kg 3 times per week for 2 months CDDO-Me treatment significantly reduced splenic cellularity, decreased serum autoantibody levels, and attenuated renal disease. Arthritis Rheumatol. 2014 Nov;66(11):3129-39
MMTV-neu transgenic mice ER-negative mammary tumor model Oral diet 60 mg/kg diet 45 weeks Prevent ER-negative mammary tumor formation, CDDO-Me significantly delayed tumorigenesis Clin Cancer Res. 2008 Jul 15;14(14):4556-63.
129/Sv and C57BL/6 female mice Total body irradiation (TBI) model Oral 400 mg/kg diet 3 days To evaluate the protective effect of CDDO-EA against acute gastrointestinal toxicity and DNA damage induced by total body irradiation (TBI). Results showed that CDDO-EA pretreatment significantly improved mouse survival, reduced gastrointestinal damage, and accelerated DNA damage repair. Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):E2949-55

Bardoxolone/巴多索隆 动物研究

Dose Mice: 3 mg/kg[3] (i.p.) Cynomolgus monkey: 5 mg/kg - 300 mg/kg[4] (p.o.)
Administration i.p., p.o.

Bardoxolone/巴多索隆 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT00529113 Pancreatic Neoplasms ... 展开 >> Pancreatic Cancer 收起 << Phase 1 Phase 2 Terminated(To pursue other ind... 展开 >>ications) 收起 << - United States, Colorado ... 展开 >> Rocky Mountain Cancer Center (US Oncology) Denver, Colorado, United States United States, Florida Cancer Centers of Florida (US Oncology) Ocoee, Florida, United States United States, Indiana Central Indiana Cancer Centers (US Oncology) Indianapolis, Indiana, United States United States, Texas Sammons Cancer Center (US Oncology) Dallas, Texas, United States, 75246 United States, Washington Northwest Cancer Specialist- Vancouver Cancer Specialist (US Oncology) Vancouver, Washington, United States 收起 <<
NCT01500798 Chronic Kidney Disease ... 展开 >> Type 2 Diabetes 收起 << Phase 1 Terminated(IDMC recommendation... 展开 >> for safety concerns) 收起 << - -
NCT01598363 Healthy Volunteers Phase 1 Completed - United States, Wisconsin ... 展开 >> Spaulding Clinical Research, LLC West Bend, Wisconsin, United States, 53095 收起 <<

Bardoxolone/巴多索隆 参考文献

[1]Kasibhatla S, et al. MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps. Cancer Res. 2007 Jun 15;67(12):5865-71.

Bardoxolone/巴多索隆 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.03mL

0.41mL

0.20mL

10.17mL

2.03mL

1.02mL

20.34mL

4.07mL

2.03mL

Bardoxolone/巴多索隆 技术信息

CAS号218600-44-3
分子式C31H41NO4
分子量 491.66
SMILES Code O=C([C@]1(CC[C@@]2(C)[C@]3(C)CCC4C(C)(C)C(C(C#N)=C[C@]4(C)C3=C5)=O)CCC(C)(C)C[C@]1([H])[C@@]2([H])C5=O)O
MDL No. MFCD07772296
别名 齐墩果烷三萜化合物 ;CDDO; RTA 401
运输蓝冰
存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Sealed in dry, store in freezer, under -20°C
溶解方案

DMSO: 105 mg/mL(213.56 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用； 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶
方案 一
方案 二

Tags: Bardoxolone | 218600-44-3 | CDDO | RTA 401 | RTA401 | RTA 401 | RTA-401 | Keap1-Nrf2 Activator | NF-κB | Apoptosis | Keap1-Nrf2 | Necroptosis | 仅供科研使用 | AmBeed-信号通路专用抑制剂 | Bardoxolone/巴多索隆 纯度/质量文件 | Bardoxolone/巴多索隆 亚型比较 | Bardoxolone/巴多索隆 生物活性 | Bardoxolone/巴多索隆 动物研究 | Bardoxolone/巴多索隆 临床数据 | Bardoxolone/巴多索隆 参考文献 | Bardoxolone/巴多索隆 实验方案 | Bardoxolone/巴多索隆 技术信息

AmBeed 相关网站 AmBeed.cn AmBeed.com
AmBeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    AmBeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 AmBeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z